Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Közelgő klinikai vizsgálatok
-
Zheng LiMég nincs toborzásKognitív gyengeség
-
Techpool Bio-Pharma Co., Ltd.Még nincs toborzásEgészséges résztvevők | UlinasztatinKína
-
Istanbul University - CerrahpasaToborzásCerebrális bénulásTörökország (Türkiye)
-
Project Skin MDMég nincs toborzás
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Még nincs toborzásAkut ischaemiás stroke AIS
-
Hospital Universitario La PazMég nincs toborzásOrr-elzáródás | Bronchiolitis | Akut felső légúti fertőzésekSpanyolország
-
E-DA HospitalNational Cheng Kung University; Metal Industries Research & Development Centre (MIRDC)ToborzásObstruktív alvási apnoeTajvan
-
Assistance Publique - Hôpitaux de ParisMég nincs toborzásExtrakorporális membrán oxigenizációs szövődmény | ECMO Cannula InfectionFranciaország
-
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.ToborzásMellrák | Gyomorrák | Petefészekrák | Előrehaladott szilárd daganatok | Egyéb szilárd daganatokKína
-
Gustave Roussy, Cancer Campus, Grand ParisMég nincs toborzásAdult Carriers of a Pathogenic or Probably Pathogenic (Class 4 and 5) Germline Variation in the TP53 GeneFranciaország
-
Assistance Publique - Hôpitaux de ParisToborzásFigyelemhiányos zavarFranciaország
-
University GhentMég nincs toborzásMűtét utáni fájdalom, akut | Irreverzibilis pulpitis (fogfájás) | Pulp Necrosis, Apical PeriodontitisBelgium
Clinical Research Jobs
-
Italy - Milan
-
United States - Shrewsbury
-
United Kingdom - Leeds
-
India - Kochi
-
United States - Massachusetts - Boston
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China